Pure Global AI
NCT06329310Not yet recruiting

Xeltis Hemodialysis Access Conduit: aXess-E Study

Prospective, Non-randomized Feasibility Study to Confirm the Safety and Performance of the Xeltis Hemodialysis Access Conduit: aXess-E Study
XeltisClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
End Stage Renal Disease
Drug/Device/Intervention
aXess-E conduit
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Xeltis
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2024
End date
Dec 01, 2026
Enrollment
20 participants
Primary outcome

Primary Patency rate,Freedom from device-related SAE

Summary

A prospective, single arm, non-randomized feasibility study to confirm the safety and
 performance of the Xeltis Hemodialysis Access conduit, aXess-E, in subjects older than 18
 years with end-stage renal disease, who plan to undergo hemodialysis for at least the first 6
 months after study access creation.

ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06329310
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06329310 through Pure Global AI's free database. This phase not specified trial is sponsored by Xeltis and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.